NEW YORK (GenomeWeb News) – OncoMethylome Sciences today announced an agreement with GlaxoSmithKline Biologics for the potential use of a DNA methylation-specific biomarker for the development of immunotherapeutics.
The two firms began a collaboration in 2007, and today's agreement "marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK," said Jan Groen, CEO of OncoMethylome. He added that it "underpins our strategy of leveraging our methylation-specific PCR platform" for the development of companion diagnostics and personalized medicine.
The biomarker, the Belgian company said, allows for the analysis of non-invasive tissue samples.
Financial terms of the agreement were not disclosed.